Home › Breast Cancer › NCT06092892
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Clinical T1-2N0 ER+ Her2- Breast Cancer With Ultrasound Detected Nodal Metastases
Who can join
Ages 45 and older · Women
Full eligibility criteria
Inclusion Criteria: * Women age ≥ 45 * Clinical T1-2N0 ER+ invasive breast cancer * US detected biopsy proven axillary nodal disease * Written informed consent obtained from subject and ability for subject to comply with the requirements of the study. Exclusion Criteria: * Palpable nodes on physical exam * Her2+ or ER- invasive breast cancer * Extranodal extension \> 3 mm on nodal biopsy * More than 2 suspicious nodes on preoperative imaging
About the study
The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.
What is being tested
- Breast Surgery (BCS or mastectomy) with TAD/SNB (procedure)
- Adjuvant Radiation Therapy (radiation)
Sponsor: Alice Chung · Participants: 45 · Started: Apr 7, 2024
Contact the study team
- Clinical Trial Navigator · Phone: 310-423-5842
Official record on ClinicalTrials.gov — NCT06092892
Locations in the U.S.
| California | Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles CS Cancer at Huntington Cancer Center, Pasadena CS Cancer at Valley Oncology Medical Group, Tarzana |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.